Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1438916 | 0.98 | HTR2C (0.39) | HTR2CHTR2AHTR2BTP53TGM2 | |
| SCHEMBL14244119 | 0.89 | — | — | |
| SCHEMBL1973236 | 0.88 | HTR2C (0.45) | HTR2CHTR2AHTR2BTP53NPY5R | |
| SCHEMBL5866375 | 0.86 | CDA (0.46) | HTR2CHTR2AHTR2BTP53NPY5R | |
| Trifluoroacetic Acid SCHEMBL22588024 | 0.85 | NPY5R (0.37) | HTR2CHTR2AHTR2BTP53TGM2 | |
| SCHEMBL17138583 | 0.84 | KDM4E (0.39) | TGM2NPY5RALDH1A1KMT2AHSD11B1 | |
| SCHEMBL9202125 | 0.84 | KDM4E (0.39) | TGM2NPY5RALDH1A1KMT2AHSD11B1 | |
| SCHEMBL3093245 | 0.83 | PDE7A (0.41) | ALDH1A1MAPTPKMKMT2AHSD11B1 | |
| SCHEMBL16400703 | 0.82 | — | — | |
| SCHEMBL10807373 | 0.81 | TGM2 (0.34) | HTR2CHTR2AHTR2BTGM2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-4264599-A | HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| US-4242347-A | Hypotensive indolylalkylpiperidyl guanidines and isoureas | CIBA-GEIGY CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0004358-A1 | N-oxacyclylalkyl piperidines, process for their preparation, pharmaceutical compositions containing these compounds | CIBA-GEIGY AG (CH) | 1979-10-03 | — | — | EP | disclosed |
| US-4147786-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| EP-0000485-A1 | Piperidino-propanols, their preparation and pharmaceutical compounds containing them | CIBA-GEIGY AG (CH) | 1979-02-07 | — | — | EP | disclosed |
| US-4087531-A | CNS DEPRESSANTS, SEDATIVES, TRANQUILIZERS | BOEHRINGER INGELHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075208-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4073911-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-14 | — | — | US | disclosed |
| US-3956335-A | HYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HTR2C 3784/4885HTR2A 4183/4885HTR2B 4037/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | HTR2C 507/4885HTR2A 446/4885HTR2B 432/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HTR2C 3816/4885HTR2A 4158/4885HTR2B 4043/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | HTR2C 3291/4885HTR2A 4274/4885HTR2B 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.